为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HBV 重编程肝细胞癌肿瘤微环境：机制与治疗意义
英文原题：HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications.
查看英文原题
HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
乙型肝炎病毒（HBV）感染是全球重要的健康问题，通过直接致癌和间接机制导致肝细胞癌（HCC）。HBV通过免疫抑制、代谢适应和基质重塑重编程肿瘤微环境（TME），从而促进肿瘤进展和免疫逃逸。本综述探讨了HBV诱导的TME变化，包括表观遗传失调、免疫细胞功能障碍和纤维化，以及包括免疫检查点阻断、过继细胞治疗和代谢靶向在内的新治疗选择，以改善HBV相关HCC的预后。
展开英文摘要原文
Hepatitis B virus (HBV) infection is an important worldwide health issue and attribute to hepatocellular carcinoma (HCC) via direct oncogenic and indirect mechanisms. HBV reprograms the tumor microenvironment (TME) through immunosuppression, metabolic adaptation, and stromal remodel, allowing tumor promotion and immune evasion.
This review examines HBV-induced TME changes, including epigenetic dysregulation, immune cell dysfunction, and fibrosis, as well as new therapeutic options including immune checkpoint blockade, adoptive cell therapy, and metabolic targeting to improve outcomes in HBV-related HCC.
论文信息
- 作者
- Shen X、Huang H、Sheng J、Tang X
- 第一作者单位
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.China
- 通讯作者单位
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. drtxf@163.com.China
- 文献类型
- 综述
- 期刊
- Clinical and experimental medicine2026 Feb 11
- 原文标识
- PubMed 41673369 · DOI 10.1007/s10238-025-01851-4
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →